Cracking Glioblastoma's Code: New Hope Forged in Canadian Labs

Brain Cancer Canada injects $85,000 into pioneering research targeting recurrent glioblastoma.
Dr. Stéphane Angers at the University of Toronto leads the charge to find new therapies for treatment-resistant brain tumours.
The project explores weaknesses in hypermutant GBM cells, potentially repurposing existing drugs.

In the shadow of glioblastoma (GBM), one of brain cancer's most aggressive and treatment-resistant forms, hope glimmers anew. Brain Cancer Canada has announced a vital $85,000 research grant to Dr. Stéphane Angers at the University of Toronto, fueling a daring project: "Discovery of Druggable Vulnerabilities in Hypermutant Recurrent Glioblastoma."

For patients battling GBM, recurrence after surgery, chemotherapy, and radiation is an almost certain, devastating blow. A chilling 15% of these recurrent tumours develop mutations in the MSH6 gene, arming them against chemotherapy and triggering a "hypermutation" cascade – an explosion of additional genetic changes. Dr. Angers’ lab has uncovered a potential chink in this armour: these hypermutant cells might be uniquely vulnerable to antifolate drugs, already approved for other conditions.

This critical funding, part of Brain Cancer Canada's Brain Cancer Awareness Month announcements and backed by powerful grassroots efforts including Sault Ste Marie Warriors, Burpees for Brain Cancer, and memorial fundraisers for Bernardo Scalisi, Roxanne Tanton, and Greg McLane, will empower Dr. Angers' team to:

Uncover differences in drug sensitivity between hypermutant and non-hypermutant recurrent GBM cells.
Employ cutting-edge genetic screening to pinpoint new therapeutic targets within this resilient tumour subset.

This $85,000 grant, while significant, is part of a much larger national offensive. Brain Cancer Canada, often in collaboration with partners like the Cancer Research Society and Kindred Foundation, spearheads translational research programs aiming to fast-track discoveries into life-saving treatments for both adult and pediatric brain cancers, including DIPG^{1, 2, 4, 5, 8}. This particular project embodies the spirit of innovation, seeking to repurpose existing therapies and discover novel vulnerabilities to conquer recurrent GBM^{3, 6}.

Since 2015, Brain Cancer Canada has channeled over $2.4 million into 25 projects across nine Canadian institutions, relentlessly pursuing a future where a brain cancer diagnosis is not a death sentence. For more details on this and other research initiatives, please contact 1-855-375-1381.

Cracking Glioblastoma's Code: New Hope Forged in Canadian Labs

References

Stay Updated!